So far, that hasn’t been an issue with Roche’s drug or another BTK from Novartis called remibrutinib. All four drugs are in phase 3 testing, in a closely-fought contest to bring a new oral ...
Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results